Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could adding capecitabine boost chemo success in Triple-Negative breast cancer?

NCT ID NCT04335669

Ongoing Disease control Sponsor: Lund University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial tests whether adding the drug capecitabine to standard chemotherapy improves outcomes for people with early triple-negative breast cancer. The study involves 325 participants and aims to see if the combination leads to a higher rate of complete tumor disappearance before surgery. Pembrolizumab is also allowed in both treatment groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
capecitabine (added to standard chemotherapy drugs epirubicin, cyclophosphamide, paclitaxel, carboplatin, and pembrolizumab)
What this could lead to
If successful, this could lead to a more effective chemotherapy regimen for early triple-negative breast cancer, potentially increasing the chance of a complete response before surgery.
What could go wrong
This is a phase 3 trial, but results are not yet available. Adding capecitabine may increase side effects without improving outcomes, and the study only includes specific patient types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm Pathologic Complete Response triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER TRIPLE NEGATIVE BREAST NEOPLASMS

Contacts and locations

Locations

  • Aalborg Universitetshospita

    Aalborg, 9000, Denmark

  • Academical Hospital, Department of Oncology

    Uppsala, 753 09, Sweden

  • Capio S:t Göran Hospital, Department of Oncology

    Stockholm, 112 19, Sweden

  • Centralsjukhuset i Kristianstad

    Kristianstad, Skåne County, 291 85, Sweden

  • Gävle hospital, Department of Oncology

    Gävle, 803 24, Sweden

  • Halmstad Hospital, Department of Surgery

    Halmstad, 302 33, Sweden

  • Karlstad Hospital

    Karlstad, 652 30, Sweden

  • Nordsjællands Hospital

    Hillerød, 3400, Denmark

  • Norrland University Hospital, Department of Oncology

    Umeå, 907 37, Sweden

  • Regionsjælland Næstved Sygehus

    Næstved, 4700, Denmark

  • Rigshospitalet

    Copenhagen, 2100, Denmark

  • Ryhov Hospital

    Jönköping, 551 85, Sweden

  • Sahlgrenska University Hospital, Department of Oncology

    Gothenburg, 413 46, Sweden

  • Skåne University Hospital, Department of Oncology

    Malmö, 20501, Sweden

  • Sundsvall hospital

    Sundsvall, 851 86, Sweden

  • Sydvestjysk Sygehus

    Esbjerg, 6700, Denmark

  • Södersjukhuset, Department of Oncology

    Stockholm, 118 61, Sweden

  • Södra Älvsborgs Hospital

    Borås, 501 82, Sweden

  • Sønderborg sygehus

    Sønderborg, 6300, Denmark

  • Vejle Hospital

    Vejle, Region Syd, 7100, Denmark

  • Vejle syghus

    Vejle, 7100, Denmark

  • Västmanlands Hopsital Västerås

    Västerås, 721 89, Sweden

  • Växjö Hospital, Department of Oncology

    Vaxjo, 352 34, Sweden

  • Örebro University Hospital, Department of Oncology

    Örebro, 701 85, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.